Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q2
Sell
-1,300
Closed -$17K 10573
2014
Q1
$17K Sell
1,300
-9,100
-88% -$135K ﹤0.01% 8301
2013
Q4
$156K Buy
10,400
+8,900
+593% +$114K ﹤0.01% 5555
2013
Q3
$17K Sell
1,500
-6,600
-81% -$55K ﹤0.01% 8250
2013
Q2
$64K Buy
+8,100
New +$51.6K ﹤0.01% 6419

Other funds holding HALO

UBS's HALO Position: Q3 2014 in Review

UBS increased its Halozyme (HALO) stake by 346% in Q3 2014, buying an estimated $988K and bringing the position to 133,766 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #3397.

UBS first reported a position in HALO in Q2 2013 and has held it in 6 quarters since. 121 funds tracked by Wall St. Rank hold HALO as of Q3 2014.

  • UBS held 133,766 shares of Halozyme worth $1.22M as of Q3 2014.
  • UBS bought 103,746 Halozyme shares in Q3 2014, an estimated $988K.
  • Halozyme made up ﹤0.01% of UBS's portfolio in Q3 2014, its #3397 holding.
  • UBS first reported a position in Halozyme in Q2 2013 and has held it in 6 quarters since.
  • 121 funds tracked by Wall St. Rank held Halozyme as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.